Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05812976 · ClinicalTrials.gov registry record
Novel Index (PIMR) in PAH
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 22
- Enrollment target
NCT05812976 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 22 participants.
The verdict
NCT05812976 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The chief regulator of resistance in pulmonary arterial hypertension (PAH) is the small arteries. In the heart, the invasive measurement of the resistance of the small arteries has been shownto be safe, easy, reliable, and prognostic. This study is intended to translate prior work in heart arteries to the PAH space and invasively measure the resistance of the small arteries of the lung (pulmonary index of microcirculatory resistance \[PIMR\]) and the coronary artery supplying the right ventricle (acute marginal of the RCA; RV-IMR). Importantly, these measurements will be made during standard of care cardiac catheterizations (right heart catheterization \[RHC\] +/- left heart catheterization). The correlation between these new indices and the standard ones measured during RHC typically used to determine the severity of pulmonary hypertension will be analyzed. In addition, among newly diagnosed patients, the study will evaluate how these indices change 6 months after starting treatment. Finally, the association of these indices with clinical outcomes at 1 year will be assessed. The findings from this study may deliver an immediate impact to patient care by identifying a new metric to help better identify those who may benefit from a more intensive, personalized treatment regimen.
Interventions
- OTHER Pulmonary Index of Microcirculatory Resistance
- OTHER Right Ventricle Index of Microcirculatory Resistance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2025-04-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05812976
The ClinicalTrials.gov registry entry for NCT05812976 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pulmonary Index of Microcirculatory Resistance is the first listed.
NCT05812976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05812976 about?
NCT05812976 is a clinical study titled "Novel Index (PIMR) in PAH". The chief regulator of resistance in pulmonary arterial hypertension (PAH) is the small arteries. In the heart, the invasive measurement of the resistance of the small arteries has been shownto be safe, easy, reliable, and prognostic. This study is intended to translate prior work in heart arteries ...
What is the current status of trial NCT05812976?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2023-02-01. Estimated completion is 2025-04-08.
What interventions are being tested in trial NCT05812976?
The interventions under investigation include: Pulmonary Index of Microcirculatory Resistance (OTHER), Right Ventricle Index of Microcirculatory Resistance (OTHER).
Who is sponsoring clinical trial NCT05812976?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.